Janux Therapeutics, Inc. · NASDAQ:JANX
Janux Therapeutics — Cantor Global Healthcare Conference 2026
21 slides from Janux Therapeutics's conference presentation, Sep 11, 2026
Slide 1: Creating Transformative Medicines to Improve Patients’ Lives
Creating Transformative Medicines to Improve Patients’ Lives Cantor Global Healthcare Conference 2026 September 2026
Slide 2: Forward-Looking Statements and Disclaimers
Forward-Looking Statements and Disclaimers This presentation includes certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking sta
Slide 3: Janux’s foundational platform technologies
Janux’s foundational platform technologies Engineering precision into immune engagement TRACTr TRACIr ARM Masking enables tumor activated, potent T- Masked CD28 co-stimulation enhances T- Novel T-Cell binder technology targeting cell engagement with reduced systemic cell activity at the tumor site p
Slide 4: Prostate Cancer Franchise
Prostate Cancer Franchise } Janux
Slide 5: Janux prostate cancer franchise addresses patient needs across the disease spectrum
Janux prostate cancer franchise addresses patient needs across the prostate cancer disease spectrum Estimated Treated PCa Patient Population* Aim to Treat Both HSPC and CRPC Patients HSPC 300,000 CRPC • Prostate cancer represents one of the largest oncology markets, spanning both HSPC and CRPC Numbe
Slide 6: Phase 1a evaluations provided path forward for expansion and pivotal studies
Phase 1a evaluations provided path forward for expansion and pivotal studies JANX007 Overview* Phase 1a dose escalation study in 109 patients and Phase 1b studies initiated JANX007 has achieved durable responses and rPFS coupled with a manageable safety profile that compares favorably to both ap
Slide 7: JANX014: Double-masked PSMA-targeted TRACTr
JANX014: Double-masked PSMA-targeted TRACTr Disciplined exploration to extend the prostate franchise JANX014 Overview • JANX014 is a double-masked, PSMA-targeted TRACTr designed to evaluate safety, tolerability, and clinical utility • Based upon learnings from our JANX008 program, JANX014 may reduce
Slide 8: JANX013: PSMA×CD28 Tumor-Activated TRACIr
JANX013: PSMA×CD28 Tumor-Activated TRACIr CD28 co-stimulatory amplifier designed for deeper, more durable responses JANX013 Overview • JANX013 is a double-masked, CD28 co-stimulatory TRACIr initially developed for use in combination with JANX007 • Potentially provides deeper more durable anti-tumor
Slide 9: Adaptive Immune Response Modulator (ARM) Platform
Adaptive Immune Response Modulator (ARM) Platform Redesigned T-cell engagers
Slide 10: ARM platform combines safety and convenience with durable responses
ARM platform is designed to combine safety and convenience with durable responses to create new treatment possibilities in AID and heme-onc ARM NHP studies highlight potential for outpatient / community-based dosing Durability of Response CAR-T ARM Durability • A single, SC dose drove deep, durable
Slide 11: ARM bispecific platform overcomes TCE limitations
Janux has developed its ARM bispecific platform to overcome TCE limitations and deliver transformative therapies Designed for Competitive Differentiation Efficacy Safety Convenience Deep, durable B-cell depletion in Favorable tolerability in NHP studies Safety and dosing supports potential NHP studi
Slide 12: Key features of the ARM platform and CD19-ARM
Key features of the ARM platform and CD19-ARM T-Cell Binding Domain Target Cell Binding Domain • Proprietary domain binds directly to TCR beta variable domain of TRBV6 rather than CD3 • CD19 selected as first target • Broad B-cell coverage may be key to attaining • TRBV6 represents ~3-5% of overall
Slide 13: JANX011 is being evaluated in an ongoing HNV Phase 1 dose escalation study
JANX011 is being evaluated in an ongoing HNV Phase 1 dose escalation study Dose Escalation (n = 4-6 per cohort) Key Readouts and Objective SC single-dose SC repeat-dose Key Readouts 3mg Zmg • Identify pharmacologically active dose for AID studies • B-cell depletion 1mg Ymg • Safety and CRS 0.3mg Xmg
Slide 14: JANX011 designed for commercial scale up and broad patient access
JANX011 designed for commercial scale up and broad patient access Manufacturing & Formulation SC formulation compares favorably to approved SC drugs 250 • Robust and highly scalable manufacturing process with demonstrated 500 L clinical scale Concentration (mg/mL) 200 Belimumab Efgartigimod • MAb-li
Slide 15: ARM NHP Studies
ARM NHP Studies } Janux
Slide 16: CD19-ARM potential best-in-class safety multiple in NHP
CD19-ARM potential best-in-class safety multiple in NHP relative to CD19-TCEs and in vivo CAR-T Deep B cell depletion without CRS Janux CD19-ARM Attributes JANX011 CD19-ARM *CLN-978 †Blincyto ‡CPTX2309-S 0 0 0 0 (from pre-dose to day 7) (from pre-dose to day 7) (from pre-dose to day 7) (from pre-dos
Slide 17: CD19-ARM drives deep B cell depletion in bone marrow, spleen, and lymph nodes
CD19-ARM drives deep B cell depletion in bone marrow, spleen, and lymph nodes in NHPs Supra-therapeutic levels without dose limiting CRS highlights best in class opportunity Blood Bone Marrow Spleen Lymph Node Deep Tissue Depletion Mesenteric Axillary Inguinal 1,000 8,000 120,000 80,000 100,000 800
Slide 18: A single SC dose of CD19- or CD20-ARM demonstrated durable memory B-cell reset
A single SC dose of CD19- or CD20-ARM demonstrated durable memory B-cell reset in NHPs Consistent NHP profile observed across the ARM platform CD19-ARM (1+1) CD20-ARM (2+1) 800 1000 0.1 mpk SC 0.5 mpk SC 3 mpk SC 3 mpk SC 100 mpk SC B cell count / μL blood Cell counts / μL blood 700 B cell phenotype
Slide 19: Corporate Summary
Corporate Summary } Janux
Slide 20: Key catalysts
Key catalysts Well-funded to generate robust proof-of-concept across our enabling technology platforms Program 2025 1H 2026 2H 2026 1H 2027 Updates Single-agent ✓ FPI in Phase 1b 1H 2027 TRACTr JANX007 Darolutamide combo ✓ FPI in Phase 1 2H 2027 PSMA x CD3 Single-agent FPI in Phase 2 TBA TRACTr JANX
Slide 21: JanuxRx.com
JanuxRx.com 10955 Vista Sorrento Parkway San Diego, CA 92130 investors@januxrx.com
Janux Therapeutics — Cantor Global Healthcare Conference 2026 on 6ix